We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
(-9.8%)
Cap. Flow
-$772M
Cap. Flow
% of AUM
-28.57%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphatec Holdings
ATEC
|
+$39.7M |
| 2 |
Humana
HUM
|
+$32.6M |
| 3 |
MAZE
Maze Therapeutics
MAZE
|
+$29.9M |
| 4 |
Avalo Therapeutics
AVTX
|
+$25.8M |
| 5 |
ALMR
Alamar Biosciences
ALMR
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$78.9M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$71.8M |
| 3 |
CG Oncology
CGON
|
+$66.7M |
| 4 |
argenx
ARGX
|
+$55.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$46.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.44% |
| 2 | Miscellaneous | 3.68% |
| 3 | Financials | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
COAG
76
Hemab Therapeutics
COAG
$2.09B
| $5.88M | 0.22% |
+160,000
| New | +$4.41M |
|
77
GH Research
GHRS
$1.92B
| $5.57M | 0.21% |
+207,240
| New | +$4.33M |
|
78
Waters Corp
WAT
$40.7B
| $5.27M | 0.19% |
+14,040
| New | +$4.79M |
|
|
RACC
79
Research Alliance Corp III
RACC
$195M
| $4.28M | 0.16% |
+400,000
| New | +$4.17M |
|
|
JATT
80
JATT II Acquisition Corp
JATT
$93.6M
| $2.84M | 0.11% |
+250,000
| New | +$2.66M |
|
81
Pulmonx
LUNG
$102M
| $978K | 0.04% |
752,541
| – | – |
|
|
YARW
82
Yarrow Bioscience
YARW
$98.8M
| $596K | 0.02% |
18,322
| – | – |
|
83
Cyclerion Therapeutics
CYCN
$17.7M
| $532K | 0.02% |
+156,890
| New | +$509K |
|
84
Apogee Therapeutics
APGE
$10.2B
| – | – |
-478,667
| Closed | -$40.3M |
|
85
BioMarin Pharmaceuticals
BMRN
$12.5B
| – | – |
-497,020
| Closed | -$28.1M |
|
86
Celcuity
CELC
$4.33B
| – | – |
-29,198
| Closed | -$3.33M |
|
|
87
CG Oncology
CGON
$6.59B
| – | – |
-984,783
| Closed | -$66.7M |
|
88
Compass Therapeutics
CMPX
$432M
| – | – |
-1,965,106
| Closed | -$10.4M |
|
89
Centene
CNC
$32B
| – | – |
-330,000
| Closed | -$10.8M |
|
|
CNTA
90
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-1,986,768
| Closed | -$78.9M |
|
91
CVS Health
CVS
$119B
| – | – |
-290,700
| Closed | -$20.9M |
|
92
Denali Therapeutics
DNLI
$3.84B
| – | – |
-296,324
| Closed | -$5.69M |
|
93
enGene Therapeutics
ENGN
$122M
| – | – |
-2,456,870
| Closed | -$16.7M |
|
94
Establishment Labs
ESTA
$2.11B
| – | – |
-463,600
| Closed | -$26.3M |
|
95
Fulcrum Therapeutics
FULC
$294M
| – | – |
-3,134,922
| Closed | -$24M |
|
96
Harrow
HROW
$1.4B
| – | – |
-156,419
| Closed | -$5.52M |
|
97
Illumina
ILMN
$32.6B
| – | – |
-229,215
| Closed | -$28.3M |
|
|
NUVL
98
DELISTED
Nuvalent
NUVL
| – | – |
-700,429
| Closed | -$71.8M |
|
99
Penumbra
PEN
$12.7B
| – | – |
-105,352
| Closed | -$34.6M |
|
100
Praxis Precision Medicines
PRAX
$9.63B
| – | – |
-9,976
| Closed | -$3.21M |
|
Similar funds
CWM
M
AG
NIM
GC
BIAS
CCM
ACP
Braidwell's Q2 2026 Portfolio in Review
As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Humana worth $45.5M.
- Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
- Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
- Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
- Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
- Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
- Braidwell opened 24 new positions and closed 23 in Q2 2026.
- Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.
Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.